Naohiro Sekiguchi, MD, PhD, National Hospital Organization Disaster Medical Center, Tachikawa, Japan, presents data from a Phase II trial investigating tirabrutinib, a second-generation BTK inhibitor (BTKi), in symptomatic Waldenström's macroglobulinemia (WM). He also mentions its potential use for treating Bing-Neel syndrome, with various case reports showing it penetrates the blood-brain barrier. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
